Loading...
  • vaccination
  • Finally, in vivo secretion of the vesicle-bound antigen either by tumors or by vaccination with naked DNA protects against soluble antigen-secreting tumors. (aacrjournals.org)
  • We conclude that the mode of secretion can determine the immunogenicity of tumor antigens and that manipulation of the mode of antigen secretion may be used to optimize antitumor vaccination protocols. (aacrjournals.org)
  • Growing tumors with such shared tumor antigens that were, at least initially, strictly located outside of secondary lymphoid organs were successfully controlled by specific DC vaccination. (rupress.org)
  • However, to be effective, DC vaccination usually had to be initiated before or within a few days after tumor cell transfer. (rupress.org)
  • In tumor prevention studies, vaccination with S. cerevisiae expressing TAA has been shown to protect against tumor challenge ( 1 , 7 ). (aacrjournals.org)
  • Protein
  • Here we examine the immunogenicity of the same model antigen secreted by live tumors either in association with membrane vesicles (exosomes) or as a soluble protein. (aacrjournals.org)
  • To test this hypothesis, we have analyzed the immune response induced in vivo by tumors secreting an antigen either specifically coupled to membrane vesicles or freely as a soluble protein. (aacrjournals.org)
  • We used adenoviral expression of Macrophage Inflammatory Protein 1α (MIP 1α) to recruit DCs into hTert-Ad infected tumors and Ad-Flt3L to expand DCs within the tumor nodules during virotherapy. (jimmunol.org)
  • The gene encoding the C18-defined antigen was identified as a mutated form of a mouse mitogen-activated protein kinase, ERK2, and a peptide incorporating the resulting amino acid substitution (lysine to glutamine) was efficiently recognized by C18. (pnas.org)
  • Extensive efforts to isolate antigen-loss variants of CMS5 were unsuccessful, suggesting that the mutated mitogen-activated protein kinase is essential for maintenance of the malignant phenotype. (pnas.org)
  • Using a CMS5-specific CTL clone to screen a cDNA library, we identified a mutated form of mitogen-activated protein kinase as the source of the CMS5-specific antigen. (pnas.org)
  • Additionally, tumor therapy studies have shown that when tumor-bearing mice are vaccinated with S. cerevisiae constructs expressing the appropriate point-mutated Ras protein, tumor growth is slowed ( 11 , 14 ). (aacrjournals.org)
  • stimulation
  • Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. (uniprot.org)
  • Furthermore, the level of tumor antigen-dependent co-stimulation supported by the DART molecules correlated with the level of tumor target expression. (aacrjournals.org)
  • Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL," The Journal of Immunology , vol. 165, no. 2, pp. 948-955, 2000. (hindawi.com)
  • To understand the relationship between TCR density and antigen affinity for TCR in the outcome of stimulation with antigen and differentiation of CTL recognizing tumor antigen, we analyzed perforin induction in ovarian tumor-associated lymphocytes in response to the smallest possible changes in the atomic forces of interaction between antigen and TCR. (aacrjournals.org)
  • We also observed that PD-1 regulates NY-ESO-1-specific CD8 + T cell expansion upon chronic antigen stimulation. (rupress.org)
  • targets
  • Consistent with this train of thought, the targets of approved antibody therapies are predominantly extracellular antigens ( 1 ). (frontiersin.org)
  • cancer
  • First, products of oncogenes and the tumor suppressor gene products and cancer-Testis antigen, oncofetal antigen, differentiation antigen, and angiogensesis associated antigen, and immune checkpoint molecule. (hstalks.com)
  • This review aims to describe the vast spectrum of tumor antigens and strategies to develop cancer vaccines. (asm.org)
  • The first generation of antibody-based therapies were based on the use of tumor antigen (TA)-specific allogeneic, autologous, or xenogeneic polyclonal antibodies, which were ill suited as cancer-specific therapies because of their limited or lack of specificity and reproducibility. (aacrjournals.org)
  • Cancer, differentiation and embryonic antigens: some central problems. (pubmedcentralcanada.ca)
  • These findings should advance our current knowledge in devising antitumor immunotherapeutic remedies to complement virotherapy-mediated tumor destruction and restrict cancer remission in clinical settings. (aacrjournals.org)
  • ACRBP is as a cancer-testis antigen, a class of genes whose expression is selective to the testes but frequently activated in a wide range of tumors. (aacrjournals.org)
  • Here, we find that ACRBP is both necessary and sufficient for paclitaxel resistance in ovarian cancer cell lines and ovarian tumor explants. (aacrjournals.org)
  • Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients," Clinical Cancer Research , vol. 14, no. 3, pp. 764-771, 2008. (hindawi.com)
  • Recursive partitioning as an approach to selection of immune markers for tumor diagnosis," Clinical Cancer Research , vol. 9, no. 14, pp. 5120-5126, 2003. (hindawi.com)
  • Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer," American Journal of Reproductive Immunology , vol. 57, no. 4, pp. 243-249, 2007. (hindawi.com)
  • Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q," International Journal of Cancer , vol. 104, no. 1, pp. 73-84, 2003. (hindawi.com)
  • Furthermore the role of p53 as tumor antigen and its potential role as target antigen in ovarian cancer is summarized. (biomedcentral.com)
  • However, before reviewing these studies we will briefly introduce some general aspects of the cellular immune system including antigen encounter, antigen processing and presentation and factors influencing the outcome of the immune response in ovarian cancer. (biomedcentral.com)
  • Clinical benefits of cancer immunotherapies are often not evident with the commonly used radiographic measures of objective tumor response (e.g. (aacrjournals.org)
  • These antigens have been incorporated into cancer vaccines currently in clinical trials ( 11-19 ). (aacrjournals.org)
  • foreign antigens
  • However, while vaccines have proven to be effective in combating pathogenic microorganisms, based on the immune recognition of these foreign antigens, vaccines aimed at inducing effective antitumor activity are still unsatisfactory. (asm.org)
  • immunosurveillance
  • However, the "immunosurveillance of tumors" theory independently postulated by Burnet ( 19 - 21 ) and Thomas ( 173 ) has not held the original promise, and much skepticism has been raised by different authors. (asm.org)
  • human tumors
  • Unique TAAs are now being frequently found in several human tumors, although their use in clinical trials is difficult for the time required to characterize unique TAAs at a single patient level ( 8 , 9 , 13 ). (aacrjournals.org)
  • We also isolated two human T cell clones specific for WT1RMFPNAPYL, one of which recognizes human tumors expressing this antigen. (washington.edu)
  • peptides
  • Our data demonstrate that MUC1-derived peptides are tumor antigens in AML and several other hematological malignancies that could potentially be used for immunotherapeutic approaches. (aacrjournals.org)
  • Gene
  • We report here the use of gene expression profiling to identify BAX-δ as a novel candidate tumor antigen in ALL. (aacrjournals.org)
  • T cell receptor (TCR) gene transfer employing high affinity TCRs recognizing defined tumor-associated antigens can potentially circumvent these challenges. (washington.edu)
  • chemically induced
  • Invernizzi G, Parmiani G. Tumour-associated transplantation antigens of chemically induced sarcomata cross reacting with allogeneic histocompatibility antigens. (pubmedcentralcanada.ca)
  • Resistance does not generally extend to other syngeneic tumors induced by the same carcinogen, but is restricted to challenge with the tumor used for immunization, indicating that the antigenic polymorphism of chemically induced sarcomas is apparently quite extensive ( 7 , 8 ). (pnas.org)